Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Atrial Fibrillation | Research article

Risk factors for medication non-adherence among atrial fibrillation patients

Authors: Stephanie R. Reading, Mary Helen Black, Daniel E. Singer, Alan S. Go, Margaret C. Fang, Natalia Udaltsova, Teresa N. Harrison, Rong X. Wei, In-Lu Amy Liu, Kristi Reynolds, for the ATRIA-CVRN Investigators

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Atrial fibrillation (AF) patients are routinely prescribed medications to prevent and treat complications, including those from common co-occurring comorbidities. However, adherence to such medications may be suboptimal. Therefore, we sought to identify risk factors for general medication non-adherence in a population of patients with atrial fibrillation.

Methods

Data were collected from a large, ethnically-diverse cohort of Kaiser Permanente Northern and Southern California adult members with incident diagnosed AF between January 1, 2006 and June 30, 2009. Self-reported questionnaires were completed between May 1, 2010 and September 30, 2010, assessing patient socio-demographics, health behaviors, health status, medical history and medication adherence. Medication adherence was assessed using a previously validated 3-item questionnaire. Medication non-adherence was defined as either taking medication(s) as the doctor prescribed 75% of the time or less, or forgetting or choosing to skip one or more medication(s) once per week or more. Electronic health records were used to obtain additional data on medical history. Multivariable logistic regression analyses examined the associations between patient characteristics and self-reported general medication adherence among patients with complete questionnaire data.

Results

Among 12,159 patients with complete questionnaire data, 6.3% (n = 771) reported medication non-adherence. Minority race/ethnicity versus non-Hispanic white, not married/with partner versus married/with partner, physical inactivity versus physically active, alcohol use versus no alcohol use, any days of self-reported poor physical health, mental health and/or sleep quality in the past 30 days versus 0 days, memory decline versus no memory decline, inadequate versus adequate health literacy, low-dose aspirin use versus no low-dose aspirin use, and diabetes mellitus were associated with higher adjusted odds of non-adherence, whereas, ages 65–84 years versus < 65 years of age, a Charlson Comorbidity Index score ≥ 3 versus 0, and hypertension were associated with lower adjusted odds of non-adherence.

Conclusions

Several potentially preventable and/or modifiable risk factors related to medication non-adherence and a few non-modifiable risk factors were identified. These risk factors should be considered when assessing medication adherence among patients diagnosed with AF.
Literature
1.
go back to reference Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Am Med Assoc. 2001;285(18):2370–5.CrossRef Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Am Med Assoc. 2001;285(18):2370–5.CrossRef
2.
go back to reference Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.CrossRef Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.CrossRef
3.
go back to reference Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.CrossRef Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.CrossRef
4.
go back to reference Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:447–54.CrossRef Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:447–54.CrossRef
5.
go back to reference Steinberg BA, Piccini J. Anticoagulation in atrial fibrillation. BMJ. 2014;14(348):g2116.CrossRef Steinberg BA, Piccini J. Anticoagulation in atrial fibrillation. BMJ. 2014;14(348):g2116.CrossRef
6.
go back to reference Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. JAMA. 2015;314:278–88.CrossRef Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. JAMA. 2015;314:278–88.CrossRef
7.
go back to reference Van Gelder I, Rienstra M, Crijns H, Olshansky B. Rate control in atrial fibrillation. Lancet. 2006;388:818–28.CrossRef Van Gelder I, Rienstra M, Crijns H, Olshansky B. Rate control in atrial fibrillation. Lancet. 2006;388:818–28.CrossRef
8.
go back to reference Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132(17):1604–12.CrossRef Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation. 2015;132(17):1604–12.CrossRef
9.
go back to reference Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167(3):246–52.CrossRef Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167(3):246–52.CrossRef
10.
go back to reference Broderick JP, Bonomo JB, Kissela BM, Khoury JC, Moomaw CJ, Alwell K, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011;42:2509–14.CrossRef Broderick JP, Bonomo JB, Kissela BM, Khoury JC, Moomaw CJ, Alwell K, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011;42:2509–14.CrossRef
11.
go back to reference Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–9.CrossRef Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11(7):1295–9.CrossRef
12.
go back to reference Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167(6):810–7.CrossRef Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167(6):810–7.CrossRef
13.
go back to reference Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.CrossRef Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.CrossRef
14.
go back to reference Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229–35.CrossRef Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229–35.CrossRef
15.
go back to reference Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174:30–42.CrossRef Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174:30–42.CrossRef
16.
go back to reference Lamori JC, Mody SH, Patel AA, Schein JR, Gross HJ, Dacosta Dibonaventura M, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62.CrossRef Lamori JC, Mody SH, Patel AA, Schein JR, Gross HJ, Dacosta Dibonaventura M, et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7(2):53–62.CrossRef
17.
go back to reference Elezi S, Qerkini G, Bujupi L, Shabani D, Bajraktari G. Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study. Anadolu Kardiyol Derg. 2010:10(1):36–40. Elezi S, Qerkini G, Bujupi L, Shabani D, Bajraktari G. Management and comorbidities of atrial fibrillation in patients admitted in cardiology service in Kosovo-a single-center study. Anadolu Kardiyol Derg. 2010:10(1):36–40.
18.
go back to reference Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract. 2001;51(472):884-6, 889-91. Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract. 2001;51(472):884-6, 889-91.
19.
go back to reference Kim EJ, Yin X, Fontes JD, Magnani JW, Lubitz SA, McManus DD, et al. Atrial fibrillation without comorbidities: prevalence, incidence and prognosis (from the Framingham heart study). Am Heart J. 2016;177:138–44.CrossRef Kim EJ, Yin X, Fontes JD, Magnani JW, Lubitz SA, McManus DD, et al. Atrial fibrillation without comorbidities: prevalence, incidence and prognosis (from the Framingham heart study). Am Heart J. 2016;177:138–44.CrossRef
20.
go back to reference Sanfeliz-Gimeno G, Rodriguez-Bernal C, Hurtado I, Baizauli-Perez C, Librero J, Peiro S. Adherence to oral anticoagulants in patients with atrial fibrillation-a population based retrospective cohort study linking health information systems in the Valencia region. Spain: a study protocol. BMJ Open. 2015:5(10):e007613. https://doi.org/10.1136/bmjopen-2015-007613. Sanfeliz-Gimeno G, Rodriguez-Bernal C, Hurtado I, Baizauli-Perez C, Librero J, Peiro S. Adherence to oral anticoagulants in patients with atrial fibrillation-a population based retrospective cohort study linking health information systems in the Valencia region. Spain: a study protocol. BMJ Open. 2015:5(10):e007613. https://​doi.​org/​10.​1136/​bmjopen-2015-007613.
22.
go back to reference Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853–60.CrossRef Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853–60.CrossRef
23.
go back to reference Chen S-Y, Wu N, Gulseth M, LaMori J, Bookhart BK, Boulanger L, et al. One-year Adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm. 2013;19(4):291–301.CrossRef Chen S-Y, Wu N, Gulseth M, LaMori J, Bookhart BK, Boulanger L, et al. One-year Adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm. 2013;19(4):291–301.CrossRef
24.
go back to reference Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015;73(3–4):184–91.CrossRef Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015;73(3–4):184–91.CrossRef
25.
go back to reference MacEdo AF, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink. Thromb Res. 2015;136(2):250–60.CrossRef MacEdo AF, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink. Thromb Res. 2015;136(2):250–60.CrossRef
26.
go back to reference Gage BF, Van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–92.CrossRef Gage BF, Van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287–92.CrossRef
27.
go back to reference Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther. 2013;35(8):1201–10.CrossRef Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther. 2013;35(8):1201–10.CrossRef
28.
go back to reference Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25:1801–8.CrossRef Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25:1801–8.CrossRef
30.
go back to reference Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.CrossRef Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41.CrossRef
31.
go back to reference Derose SF, Contreras R, Coleman KJ, Koebnick C, Jacobsen SJ. Race and ethnicity data quality and imputation using U.S. census data in an integrated health system: the kaiser permanente Southern California experience. Med Care Res Rev. 2013;70(3):330–45.CrossRef Derose SF, Contreras R, Coleman KJ, Koebnick C, Jacobsen SJ. Race and ethnicity data quality and imputation using U.S. census data in an integrated health system: the kaiser permanente Southern California experience. Med Care Res Rev. 2013;70(3):330–45.CrossRef
32.
go back to reference Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250. https://doi.org/10.1161/JAHA.113.000250. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250. https://​doi.​org/​10.​1161/​JAHA.​113.​000250.
33.
go back to reference Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927–34.CrossRef Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927–34.CrossRef
34.
go back to reference Reading SR, Go AS, Fang MC, Singer DE, ILA L, Black MH, et al. Health literacy and awareness of atrial fibrillation. J Am Heart Assoc. 2017;6(4):e005128.CrossRef Reading SR, Go AS, Fang MC, Singer DE, ILA L, Black MH, et al. Health literacy and awareness of atrial fibrillation. J Am Heart Assoc. 2017;6(4):e005128.CrossRef
35.
go back to reference Ashburner JM, Go AS, Reynolds K, Chang Y, Fang MC, Fredman L, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015;115(1):40–6.CrossRef Ashburner JM, Go AS, Reynolds K, Chang Y, Fang MC, Fredman L, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015;115(1):40–6.CrossRef
36.
go back to reference Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, et al. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials. 1991;12:1):1–77.CrossRef Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, Hughes GH, et al. Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials. 1991;12:1):1–77.CrossRef
37.
go back to reference Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med. 2005;165(21):2508–13.CrossRef Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med. 2005;165(21):2508–13.CrossRef
38.
go back to reference Chew LD, Bradley KA, Boyko E. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;16(2):438–40. Chew LD, Bradley KA, Boyko E. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;16(2):438–40.
39.
go back to reference Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23(5):561–6.CrossRef Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23(5):561–6.CrossRef
40.
go back to reference Hoover DS, Vidrine JI, Shete S, Spears CA, Cano MA, Correa-Fernandez V, et al. Health literacy, smoking, and health indicators in African American adults. J Health Commun. 2015;20:24–33.CrossRef Hoover DS, Vidrine JI, Shete S, Spears CA, Cano MA, Correa-Fernandez V, et al. Health literacy, smoking, and health indicators in African American adults. J Health Commun. 2015;20:24–33.CrossRef
41.
go back to reference Wallace LS, Rogers ES, Roskos SE, Holiday DB, Weiss BD. Brief report: screening items to identify patients with limited health literacy skills. J Gen Intern Med. 2006;21(8):874–7.CrossRef Wallace LS, Rogers ES, Roskos SE, Holiday DB, Weiss BD. Brief report: screening items to identify patients with limited health literacy skills. J Gen Intern Med. 2006;21(8):874–7.CrossRef
42.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRef
43.
go back to reference Al-Khalili F, Lindström C, Benson L. Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. Clin Trials Regul Sci Cardiol. 2016;18:1–4.CrossRef Al-Khalili F, Lindström C, Benson L. Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. Clin Trials Regul Sci Cardiol. 2016;18:1–4.CrossRef
44.
go back to reference Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation. 2010;121:1455–8.CrossRef Baroletti S, Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation. 2010;121:1455–8.CrossRef
45.
go back to reference Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J Clin Diagnostic Res. 2016;10(12):FC40–3. Shruthi R, Jyothi R, Pundarikaksha HP, Nagesh GN, Tushar TJ. A study of medication compliance in geriatric patients with chronic illnesses at a tertiary care hospital. J Clin Diagnostic Res. 2016;10(12):FC40–3.
46.
go back to reference Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients’ perspectives on medication-related problems. Patient Educ Couns. 2007;65(3):407–15.CrossRef Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients’ perspectives on medication-related problems. Patient Educ Couns. 2007;65(3):407–15.CrossRef
47.
go back to reference Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14.CrossRef Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14.CrossRef
48.
go back to reference Hawkshead J, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis Manag Health Out. 2007;15:109–18.CrossRef Hawkshead J, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis Manag Health Out. 2007;15:109–18.CrossRef
49.
go back to reference Nunes V, Neilson J, O'Flynn N, Calvert N, Kuntze S, Smithson H, Benson J, Blair J, Bowser A, Clyne W, Crome P, Haddad P, Hemingway S, Horne R, Johnson S, Kelly S, Packam B, Patel M, Steel J. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. Other. London: NICE: National Institute for Health and Clinical Excellence; 2009. p. 1-30. Available from: http://eprints.hud.ac.uk/id/eprint/14569/1/PatelNICE43042.pdf. Nunes V, Neilson J, O'Flynn N, Calvert N, Kuntze S, Smithson H, Benson J, Blair J, Bowser A, Clyne W, Crome P, Haddad P, Hemingway S, Horne R, Johnson S, Kelly S, Packam B, Patel M, Steel J. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. Other. London: NICE: National Institute for Health and Clinical Excellence; 2009. p. 1-30. Available from: http://​eprints.​hud.​ac.​uk/​id/​eprint/​14569/​1/​PatelNICE43042.​pdf.
50.
go back to reference Monnette A, Zhang Y, Shao H, Shi L. Concordance of Adherence measurement using self-reported Adherence questionnaires and medication monitoring devices: an updated review. PharmacoEconomics. 2018;36:17–27.CrossRef Monnette A, Zhang Y, Shao H, Shi L. Concordance of Adherence measurement using self-reported Adherence questionnaires and medication monitoring devices: an updated review. PharmacoEconomics. 2018;36:17–27.CrossRef
51.
go back to reference Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Soc Adm Pharm. 2007;3(4):363–77.CrossRef Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Soc Adm Pharm. 2007;3(4):363–77.CrossRef
52.
go back to reference Jin J, Edward Sklar G, Min Sen OV, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4:269–86.CrossRef Jin J, Edward Sklar G, Min Sen OV, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4:269–86.CrossRef
53.
go back to reference Grant AB, Williams NJ, Pandi-Perumal SR. Nonadherence to antihypertensive medications in adults with high risk for obstructive sleep apnea. J Clin Hypertens. 2017;19:540–2.CrossRef Grant AB, Williams NJ, Pandi-Perumal SR. Nonadherence to antihypertensive medications in adults with high risk for obstructive sleep apnea. J Clin Hypertens. 2017;19:540–2.CrossRef
54.
go back to reference Holt EW, Muntner P, Joyce CJ, Webber L, Krousel-Wood MA. Health-related quality of life and antihypertensive medication adherence among older adults. Age Ageing. 2010;39(4):481–7.CrossRef Holt EW, Muntner P, Joyce CJ, Webber L, Krousel-Wood MA. Health-related quality of life and antihypertensive medication adherence among older adults. Age Ageing. 2010;39(4):481–7.CrossRef
55.
go back to reference Praska JL, Kripalani S, Seright AL, Jacobson TA. Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother. 2005;39:1441–5.CrossRef Praska JL, Kripalani S, Seright AL, Jacobson TA. Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother. 2005;39:1441–5.CrossRef
56.
go back to reference Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. J Am Med Assoc. 2013;310(7):699–705.CrossRef Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. J Am Med Assoc. 2013;310(7):699–705.CrossRef
57.
go back to reference Jaffe MG, Young JD. The Kaiser Permanente northern California story: improving hypertension control from 44 to 90% in 13 years (2000 to 2013). J Clin Hypertens. 2016;18:260–1.CrossRef Jaffe MG, Young JD. The Kaiser Permanente northern California story: improving hypertension control from 44 to 90% in 13 years (2000 to 2013). J Clin Hypertens. 2016;18:260–1.CrossRef
Metadata
Title
Risk factors for medication non-adherence among atrial fibrillation patients
Authors
Stephanie R. Reading
Mary Helen Black
Daniel E. Singer
Alan S. Go
Margaret C. Fang
Natalia Udaltsova
Teresa N. Harrison
Rong X. Wei
In-Lu Amy Liu
Kristi Reynolds
for the ATRIA-CVRN Investigators
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-1019-1

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue